AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19

• DOI: 10.1681/asn.2020060897
• Publication Date: 2020-10-16T23:12:39Z
• Authors: Shruti Gupta; Steven G. Coca; Lili Chan; Michal L. Melamed; Samantha K. Brenner; Salim S. Hayek; Anne Sutherland; Sonika Puri; Anand Srivastava; Amanda Leonberg-Yoo; Alexandre M. Shehata; Jennifer E. Flythe; Arash Rashidi; Edward J. Schenck; Nitender Goyal; S. Susan Hedayati; Rajany Dy; Anip Bansal; Ambarish Athavale; H. Bryant Nguyen; Anitha Vijayan; David M. Charytan; Carl E. Schulze; Min J. Joo; Allon N. Friedman; Jingjing Zhang; Marie Anne Sosa; Eric Judd; Juan Carlos Q. Velez; Mary Mallappallil; Roberta E. Redfern; Amar D. Bansal; Javier A. Neyra; Kathleen D. Liu; Amanda D. Renaghan; Marta Christov; Miklos Z. Molnar; Shreyak Sharma; Omer Kamal; Jeffery Owusu Boa...; Samuel A.P. Short; Andrew J. Admon; Meghan E. Sise; Wei Wang; Chirag R. Parikh; David E. Leaf
• Keywords: Renal replacement therapy; 2019-20 coronavirus outbreak; Nephrology

Significance Statement Although AKI is an important sequela of coronavirus disease 2019 (COVID-19), data on treated with RRT (AKI-RRT) in patients COVID-19 are limited. In a multicenter cohort study 3099 critically ill adults admitted to intensive care units (ICUs) at 67 hospitals across the United States, one five developed AKI-RRT, 63% whom died during hospitalization. Among who survived hospital discharge, three remained dependent and six 60 days after ICU admission. The identified several patient-and hospital-level risk factors for AKI-RRT death. common among associated high mortality persistent dependence. Background (COVID-19). However, few studies have focused (AKI-RRT). Methods We conducted States. used multivariable logistic regression identify examine 28-day such patients. Results A total 637 (20.6%) within 14 admission, 350 (54.9%) 28 Patient-level included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, d -dimer, greater severity hypoxemia Predictors were older age, severe oliguria, admission fewer beds or regional density COVID-19. At end median follow-up 17 (range, 1–123 days), 403 (63.3%) had died, 216 (33.9%) discharged, 18 (2.8%) hospitalized. Of 73 (33.8%) 39 (18.1%) Conclusions rate >60%. those survive still depends remains